Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SOT109
- Development stage
- Phase 2
- Lead developer
- SOTIO Biotech AG
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
SOT109 is a preclinical antibody-drug conjugate (ADC) being developed by SOTIO Biotech. It targets cadherin-17 (CDH17), a protein highly overexpressed in colorectal cancers and other gastrointestinal cancers (gastric, pancreatic, and esophageal). The ADC utilizes fully human antibodies generated using Biocytogen’s RenMab platform. SOT109 incorporates Synaffix’s proprietary GlycoConnect HydraSpace conjugation technology with the SYNtecan E linker-payload system containing an exatecan payload (DAR=4). This design aims to improve precision targeting, overcome tumor heterogeneity, and enhance efficacy while maintaining tolerability. The exatecan payload is a topoisomerase I inhibitor. SOTIO Biotech plans to enter Phase 1 clinical trials in 2026.
02
Targets
CDH17 (Cadherin-17)
Beyond the preview
Go deeper on SOT109.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SOT109.